Reviewing Sage Therapeutics Inc. (SAGE)’s and Ionis Pharmaceuticals Inc. (NASDAQ:IONS)’s results

Both Sage Therapeutics Inc. (NASDAQ:SAGE) and Ionis Pharmaceuticals Inc. (NASDAQ:IONS) are each other’s competitor in the Biotechnology industry. Thus the compare of their dividends, analyst recommendations, profitability, institutional ownership, risk, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Sage Therapeutics Inc. 90.00M 78.43 283.92M -6.40 0.00
Ionis Pharmaceuticals Inc. 568.84M 14.29 65.45M 0.51 104.36

Table 1 showcases the top-line revenue, earnings per share (EPS) and valuation of Sage Therapeutics Inc. and Ionis Pharmaceuticals Inc.

Profitability

Table 2 demonstrates the return on assets, net margins and return on equity of Sage Therapeutics Inc. and Ionis Pharmaceuticals Inc.

Net Margins Return on Equity Return on Assets
Sage Therapeutics Inc. -315.47% -31.5% -29.8%
Ionis Pharmaceuticals Inc. -11.51% -8.8% -2.4%

Volatility & Risk

A beta of 2.76 shows that Sage Therapeutics Inc. is 176.00% more volatile than Standard and Poor’s 500. Competitively, Ionis Pharmaceuticals Inc. is 138.00% more volatile than Standard and Poor’s 500, because of the 2.38 beta.

Liquidity

Sage Therapeutics Inc.’s Current Ratio is 19.1 while its Quick Ratio is 19.1. On the competitive side is, Ionis Pharmaceuticals Inc. which has a 8 Current Ratio and a 8 Quick Ratio. Sage Therapeutics Inc. is better positioned to pay off short and long-term obligations compared to Ionis Pharmaceuticals Inc.

Analyst Ratings

The next table highlights the shown recommendations and ratings for Sage Therapeutics Inc. and Ionis Pharmaceuticals Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Sage Therapeutics Inc. 1 0 2 2.67
Ionis Pharmaceuticals Inc. 0 0 0 0.00

The average target price of Sage Therapeutics Inc. is $184.67, with potential upside of 22.67%.

Institutional & Insider Ownership

Sage Therapeutics Inc. and Ionis Pharmaceuticals Inc. has shares held by institutional investors as follows: 0% and 89.5%. Insiders held 0.1% of Sage Therapeutics Inc. shares. Competitively, 0.2% are Ionis Pharmaceuticals Inc.’s share held by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Sage Therapeutics Inc. -6.71% -17.26% -33.17% -27.69% 17.03% -34.7%
Ionis Pharmaceuticals Inc. -8.51% -1.82% 19.71% 16.26% 1.5% 6.02%

For the past year Sage Therapeutics Inc. has -34.7% weaker performance while Ionis Pharmaceuticals Inc. has 6.02% stronger performance.

Summary

Ionis Pharmaceuticals Inc. beats Sage Therapeutics Inc. on 9 of the 12 factors.

Sage Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its lead product candidate includes SAGE-547, a proprietary intravenous formulation of allopregnanolone that is in Phase III clinical development as an adjunctive therapy for the treatment of super-refractory status epilepticus (SRSE), as well as for the treatment of post-partum depression (PPD). The companyÂ’s product pipeline includes SAGE-217, a novel neuroactive steroid, which is in Phase II clinical trials for the treatment of PPD, major depressive disorders, essential tremor, and ParkinsonÂ’s diseases; and SAGE-689 a novel positive allosteric modulator of GABAA receptors that is in preclinical stage for the treatment of status epilepticus. In addition, its product pipeline that are in preclinical stage comprises SAGE-105, a novel neuroactive steroid for the treatment of orphon epilepsies; SAGE-324, a novel neuroactive steroid for the treatment of GABA hypofunction; and SAGE-718, a novel oxysterol-based positive allosteric modulator of NMDA receptors for the treatment of cerebrosterol deficit disorders, anti-NMDA receptor encephalitis, and NMDA hypofunction. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Ionis Pharmaceuticals, Inc. engages in discovering and developing RNA-targeted therapeutics. The company markets SPINRAZA, an antisense drug for spinal muscular atrophy in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein-cholesterol, and as an adjunct to lipid lowering medications and diet. Its drugs in Phase III development include volanesorsen for the treatment of patients with familial chylomicronemia syndrome and familial partial lipodystrophy; and IONIS-TTRRx, an antisense drug to treat all forms of transthyretin amyloidosis. The company also develops IONIS-HTTRx, an antisense drug to treat patients with Huntington's disease; IONIS-SOD1Rx, an antisense drug to treat patients with an inherited form of amyotrophic lateral sclerosis; AKCEA-ANGPTL3-LRx, a LICA drug for treating multiple lipid disorders or mixed dyslipidemias; IONIS-PKKRx, an antisense drug that treats patients with hereditary angioedema; IONIS-FXIRx, an antisense drug for the treatment of thrombosis; AKCEA-APO(a)-LRx, a LICA drug that reduces apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); and AKCEA-APOCIII-LRx, an antisense drug for cardiometabolic disease. In addition, it develops IONIS-AR-2.5Rx, an antisense drug that treats patients with prostate cancer; IONIS-STAT3-2.5Rx, a cancer drug; AKCEA-ANGPTL3-LRx, a LICA drug to treat multiple lipid disorders; IONIS-GCGRRx, an antisense drug to treat patients with type 2 diabetes; and IONIS-DGAT2Rx, an antisense drug to treat patients with liver disease. The company was formerly known as Isis Pharmaceuticals, Inc. and changed its name to Ionis Pharmaceuticals, Inc. in December 2015. Ionis Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Carlsbad, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.